Bevacizumab
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
MARCH 2024
Q2 2024 ASP Report
Aria analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
The
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
the
to any
content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own
intellectual property rights
pharmaceutical product mentioned herein.
Table of contents
• Product comparison
• Average Sales Prices Q1 2024 & Q2 2024
• Reimbursement information for Q2 2024
• Historical ASPs
• Average Change of ASP
• WAC vs. Initial ASPs
• ASP Percent Change from WAC
• Aria ASP predictive model
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product comparison
Product Strength & Dosage Indication
Avastin1 (Genentech)
Mvasi2 (Amgen)
Zirabev3 (Pfizer)
Vegzelma4 (Celltrion)
Alymsys5 (Amneal)
Injection: Single-dose vial. 100mg/4mL, 400mg/16mL
Metastatic Colorectal Cancer, First-line Non-squamous Nonsmall Cell Lung Cancer, Recurrent Glioblastoma, Metastatic Renal Cell Carcinoma, Persistent, Recurrent, or Metastatic Cervical Cancer, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Hepatocellular Carcinoma
Cold Chain
Yes
1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=939b5d1f-9fb2-4499-80ef-0607aa6b114e
2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a562b4e-67ce-4bab-852c-d9ee71e55fb8
3. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa27acbd-d117-4350-aeee-17bc2e2c0ca4
4. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe
5. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b4040a2-a5c5-4ff0-ab45-935d7e49cf78
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
Average Sales Prices Q1 2024 & Q2 2024 (100mg/4mL)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Avg % Change Biologic Avastin (Genentech) $796.94 $698.80 $699.58 0.11% 1.76% Biosimilars Mvasi (Amgen) $697.73 $200.30 $211.53 5.61% -5.77% Zirabev (Pfizer) $613.40 $159.21 $151.58 -4.79% -7.81% Vegzelma (Celltrion) $677.40 $668.22 $636.71 -4.71% -0.30% Alymsys (Amneal) $718.60 $549.94 $532.14 -3.24% -6.43% 1.76% -5.77% -7.81% -0.30% -6.43% $0 $100 $200 $300 $400 $500 $600 $700 $800 Avastin (Genentech) Mvasi (Amgen) Zirabev (Pfizer) Vegzelma (Celltrion) Alymsys (Amneal)
ASP New ASP
ASP Change Previous
Average Sales Prices Q1 2024 & Q2 2024 (400mg/16mL)
Previous ASP New ASP
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Avg % Change Biologic Avastin (Genentech) $3,187.76 $2,795.21 $2,798.34 0.11% 1.76% Biosimilars Mvasi (Amgen) $2,790.89 $801.18 $846.13 5.61% -5.77% Zirabev (Pfizer) $2,453.60 $636.82 $606.33 -4.79% -7.81% Vegzelma (Celltrion) $2,874.40 $2,672.86 $2,546.85 -4.71% -0.30% Alymsys (Amneal) $2,709.60 $2,199.74 $2,128.57 -3.24% -6.43% 1.76% -5.77% -7.81% -0.30% -6.43% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 Avastin
(Genentech) Mvasi (Amgen) Zirabev (Pfizer) Vegzelma (Celltrion) Alymsys (Amneal) ASP Change
*Includes Medicare sequestration
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
information
Product Launch Date HCPC WAC ASP Anticipated Medicare Reimbursement* Biologic Avastin (Genentech) 1/31/2009 J9035 $796.94 $699.58 $729.69 Biosimilars Mvasi (Amgen) 7/31/2019 Q5107 $697.73 $211.53 $263.22 Zirabev (Pfizer) 1/31/2020 Q5118 $613.40 $151.58 $204.23 Vegzelma (Celltrion) 4/30/2023 Q5129 $677.40 $636.71 $681.60 Alymsys (Amneal) 10/31/2022 Q5126 $718.60 $532.14 $578.70
Reimbursement
for Q2 2024 (100mg/4mL)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Reimbursement information for
*Includes Medicare sequestration Product Launch Date HCPC WAC ASP Anticipated Medicare Reimbursement* Biologic Avastin (Genentech) 1/31/2009 J9035 $3,187.76 $2,798.34 $2,918.78 Biosimilars Mvasi (Amgen) 7/31/2019 Q5107 $2,790.89 $846.13 $1052.88 Zirabev (Pfizer) 1/31/2020 Q5118 $2,453.60 $606.33 $816.92 Vegzelma (Celltrion) 4/30/2023 Q5129 $2,709.60 $2,546.85 $2726.39 Alymsys (Amneal) 10/31/2022 Q5126 $2,874.40 $2,128.57 $2314.80
Q2 2024 (400mg/16mL)
Historical ASPs
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $100 $200 $300 $400 $500 $600 $700 $800 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Avastin (Genentech) Mvasi (Amgen) Zirabev (Pfizer) Vegzelma (Celltrion) Alymsys (Amneal)
Average Change of ASP
This graph showcases the cumulative average change in the average sales price (ASP) for the Bevacizumab family, tracking changes from the launch of biosimilars to each quarter's ASP. It highlights the evolution of ASP over the product's lifecycle and the fluctuating rate of change, providing a concise overview of pricing dynamics.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-10% -8% -6% -4% -2% 0% 2% 4% 6% 8% Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Avastin (Genentech) Mvasi (Amgen) Zirabev (Pfizer) Vegzelma (Celltrion) Alymsys (Amneal)
WAC* vs. Initial ASPs
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-32.50% -8.78% -6.79% -5.25% -3.05% -3.90% -8.72% -6.65% -1.36% -6.81% -4.54% -18.80% -7.94% -6.01% -18.83% $0 $100 $200 $300 $400 $500 $600 $700 $800 $900
Avastin (Genentech)
Mvasi (Amgen)
Zirabev (Pfizer)
Vegzelma (Celltrion)
Alymsys (Amneal)
WAC First ASP Second ASP Third ASP
ASP Percent Change from WAC*
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-90% -80% -70% -60% -50% -40% -30% -20% -10% 0% Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Avastin (Genentech) Mvasi (Amgen) Zirabev (Pfizer) Vegzelma (Celltrion) Alymsys (Amneal)
Aria ASP predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model for the Bevacizumab product family.
Avastin (Genentech) Mvasi (Amgen) Zirabev (Pfizer) Vegzelma (Celltrion) Alymsys (Amneal)
© 2024, Aria GPO and/or its affiliates.
Copyright
All rights reserved. Private and Confidential.
$0 $100 $200 $300 $400 $500 $600 $700 $800 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Predicted
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Thank you. www.ariagpo.com info@ariagpo.com